Veracyte, Inc. (NASDAQ:VCYT) is scheduled to post its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect Veracyte to post earnings of ($0.25) per share for the quarter.

Veracyte (NASDAQ:VCYT) last released its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.24). Veracyte had a negative net margin of 43.40% and a negative return on equity of 66.79%. The firm had revenue of $16.43 million for the quarter, compared to analysts’ expectations of $18.09 million. On average, analysts expect Veracyte to post $-0.92 EPS for the current fiscal year and $-0.67 EPS for the next fiscal year.

Veracyte, Inc. (NASDAQ:VCYT) opened at 8.06 on Tuesday. Veracyte, Inc. has a 52-week low of $4.82 and a 52-week high of $9.71. The firm has a 50 day moving average of $7.97 and a 200-day moving average of $8.16. The stock’s market cap is $272.99 million.

ILLEGAL ACTIVITY WARNING: “Veracyte, Inc. (VCYT) Set to Announce Earnings on Tuesday” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/07/25/veracyte-inc-vcyt-set-to-announce-earnings-on-tuesday.html.

VCYT has been the subject of several analyst reports. Cantor Fitzgerald set a $13.00 target price on shares of Veracyte and gave the stock a “buy” rating in a report on Thursday, May 4th. Janney Montgomery Scott restated a “buy” rating and issued a $15.00 target price on shares of Veracyte in a report on Wednesday, June 28th. Finally, BidaskClub lowered shares of Veracyte from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Veracyte presently has an average rating of “Buy” and a consensus price target of $11.83.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Earnings History for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.